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Summary
Objective: To investigate both prophylactic and therapeutic roles of salmon calcitonin on the articular cartilage of rabbit’s knees.
Methods: Right knee instability was produced in 30 New Zealand white rabbits by sectioning the cranial cruciate ligament (CCL). Animals were
separated into four groups: placebo prophylactic-stage group (n¼ 6), killed 8 weeks post surgery, calcitonin prophylactic-stage group (n¼ 6),
treated immediately after surgery with salmon calcitonin and killed at 8 weeks, placebo therapeutic-stage group (n¼ 9) killed at 16 weeks post
surgery and calcitonin therapeutic-stage group (n¼ 9), treated with salmon calcitonin from 8th to 16th week and killed at 16 weeks post sur-
gery. A histomorphometric study was based on the morphological changes of the articular cartilage and subchondral bone (degeneration
indexes), as well as the articular cartilage thickness, chondrocytes’ arrangement and their metabolic activity (regeneration indexes).
Results: Calcitonin groups showed smoother articular surface, no or minimal signs of ulceration, smaller osteophytes, and less subchondral
cystic formation than placebo groups. Normal distribution of chondrocytes or hypercellularity was noticed in areas of mild osteoarthritic (OA)
changes in the calcitonin groups indicating regeneration activity. Periodic Acid Schiff’s and Alcian blue staining were negative in the placebo
groups while increased absorption in the calcitonin groups revealed high anabolic activity.
Conclusions: In prophylactic stages salmon calcitonin seemed to inhibit the progression of osteoarthritis by increasing the layers of hyaline
cartilage, restoring the cellular metabolism, and decreasing the volume of osteophytes. In therapeutic stages, the hormone had a healing
effect by decreasing the subchondral cysts, regenerating the hyaline cartilage and restoring cellular metabolism. Both macroscopic and
histological ﬁndings of this study supported the biochemical results of previous studies showing the therapeutic effect of calcitonin on oste-
oarthritis.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Conservative treatment regimens for osteoarthritis treat the
symptoms but not the disease and are limited to control
pain and inﬂammation and eliminate the risk factors1,2. Fur-
thermore, it is still debated if simple analgesics are effective
as oral drugs of ﬁrst choice3,4. Steroidal and non-steroidal
anti-inﬂammatory drugs (NSAIDs) are associated with seri-
ous adverse events particularly gastrointestinal. Selective
cyclo-oxygenase-2 (COX-2) inhibitors reduce the incidence
of upper gastro-intestinal tract ulcerations, however, other
toxicities such as ﬂuid retention, hypertension, congestive
heart failure, renal insufﬁciency and a risk for cardiovascular
thrombosis may occur5,6. The therapeutic role of high
molecular weight hyaluronans, chondroitin sulfate and
glucosamine in terms of pain relief and slowing the
progression of osteoarthritis is also debated7e9. Finally,
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life span, relieves pain more predictably than it improves
joint function and can be associated with local and system-
atic complications10.
Seeking other pharmaceutical interventions, calcitonin
may be a potential agent for the treatment of osteo-
arthritis. Previous data indicated calcitonin’s safety and
effectiveness on reduction of bone turnover11 and it’s
analgesic effect in relieving osteoarthritic (OA) pain12,13.
Furthermore, there is in vivo and in vitro experimental
evidence that calcitonin acts on both cartilage and sub-
chondral bone by decreasing the enhanced turnover of
the OA subchondral bone, reducing the severity of carti-
lage OA lesions and altering the biochemical composition
and supramolecular organization of the OA cartilage
matrix14,15.
The purpose of this study was to evaluate macroscopi-
cally and microscopically the effect of salmon calcitonin
on the articular cartilage in prophylactic and therapeutic
stages of experimentally induced OA in rabbits and to
determine the preventive and/or reparative activity of the
hormone.86
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The experimental protocol was approved by the Veteri-
nary Directorate (permit no.1130), according to the Greek
Presidential Decree 160/1991, which conforms to the
EEC Directive 609/1986 for the ‘‘protection of vertebrate
animals used for experimental or other scientiﬁc purposes’’.
Thirty adult male New Zealand white rabbits (Oryctolagus
cuniculus), conventionally bred, were used. The animals
were obtained from the conventional breeding facilities of
the Hellenic Pasteur Institute and housed singly in steel
cages of 45 cm 30 cm 60 cm dimensions (IFFA
CREDO, BP 0109-69592, L’Arbresle, France) in the Labo-
ratory for Research of the Musculoskeletal System conven-
tional animal house. Their age ranged from 4 to 6 months
and their weight ranged from 3.4 to 4.9 kg. The age and
X-rays determined that the animals were skeletally mature.
Additionally, the animals were randomly assigned so that
each group had 4, 5 and 6 months old animals in them.
The temperature therein ranged between 18 and 21C, rel-
ative humidity 50e60%, the light/dark cycle was from 06:00
to 18:00 and there were 15 air changes/hour. The animals’
body weight was 2040 200 g (meanSD). They had free
access to standard rabbit pellets (14% protein, 7% fat, 15%
cellulose, 1e1.2% calcium and phosphorus) (ELVIZ Hel-
lenic Feedstuffs Ind. SA, Plati, Imathia, Greece) and tap
water.
SURGERY
All animals were operated on day 1. After induction of
general anesthesia (ketamine 25 mg/kg and midazolam
5 mg/kg intramuscularly), the right stiﬂe was shaved and
the skin prepped. Anesthetic depth was monitored through-
out the procedure by a DINAMAP vital signs monitor 1846.
Through a medial parapatellar incision the cranial cruciate
ligament (CCL) was transected macroscopically with a No
11 blade. After transection, anterior instability was manually
conﬁrmed by the anterior drawer test. The incision did not
disrupt the patellar apparatus and no patellar luxation was
needed for the CCL transection. The articular capsule and
the medial retinaculum were closed with absorbable sutures
and the skin with nylon sutures. After recovery, rabbits re-
ceived paracetamol suppository (Dolal supp. bebe, 1/3
supp.¼ 50 mg) for pain relief and were free to move in their
cages without any external immobilization. They also
received paracetamol syrup (Dolal sir. 1 ml¼ 25 mg) twice
a day the next postoperative day. The animals were
checked daily (activity, body weight, food consumption, rec-
tal temperature, wound healing) for signs of ill health for the
ﬁrst postoperative week.
TREATMENT REGIMENS
The animals were separated into four groups depending
on the time of euthanasia and the treatment received. The
ﬁrst group, placebo prophylactic-stage group included six
rabbits that were euthanised at 8 weeks in order to conﬁrm
the extension and grade of the developed OA lesions. In the
literature, the period between 6 and 8 weeks after section-
ing of the CCL is considered sufﬁcient for the development
of osteoarthritis in rabbits16. The second group, calcitonin
prophylactic-stage group included six rabbits that received
7 IU salmon calcitonin injected intramuscularly daily from
day 1 to week 8 postoperatively and then killed. The third
group, placebo therapeutic-stage group, included ninerabbits that were placebo treated and euthanised at the
sixteenth postoperative week. The fourth group, calcitonin
therapeutic-stage group, included nine rabbits that received
7 IU salmon calcitonin injected intramuscularly daily from
week 8 to week 16 postoperatively and then killed.
Euthanasia was carried out by ketamine/midazolam
premedication administered intramuscularly, followed by
slow intravenous administration of sodium thiopental
(20e30 mg/kg until cessation of cardiac function) in normal
saline drip.
SPECIMEN COLLECTION
After euthanasia, all specimens were prepared as fol-
lows: excision of the skin, osteotomy 3 cm above and be-
low the knee joint and ﬁxation of the specimens in 10%
buffered formalin for 24 h. Fixed specimens were cleared
from soft tissues and ligaments, allowing the gross exam-
ination of the articular surfaces of the femoral condyles
and tibial plateaus and charting of the specimens. The
specimens were then decalciﬁed in 10% nitric acid for 3
to 5 days. A non-operated control group was not employed
for two reasons: (1) no OA or degenerative changes were
observed in any of the joints during surgery and (2) rabbits
have very little spontaneous degeneration in their knee
joints17.
SPECIMEN EXAMINATION
The macroscopic OA lesions included (1) osteophytes,
(2) cartilage erosion (ulceration, ﬁssures) and (3) loss of
cartilage luster (softening, ﬁbrillation). The evaluation of
these lesions was based on three macroscopic parame-
ters: (1) the location, (2) the type, and (3) the size of the
OA changes. Macroscopic evaluation of the specimens in-
cluded: (1) articular surfaces digital photographing (Nikon
F5, Nikon Co, Japan) (4 objective zoom) and scanning
of the negative ﬁlms (Scanjet 3200C, Hewlett Packard,
Palo Alto, CA, USA), (2) the articular changes of the femo-
ral condyles, femoral trochlea, and tibial plateaus were
drawn on millimeter paper (2 magniﬁcation), and (3) im-
print on carbon paper of the OA changes with the use of
ink paper. The area of the articular surface involving these
lesions was measured using a Vernier caliper. The articular
surfaces of the knee were divided in ﬁve sections (IeV) in
order to deﬁne the areas with the highest incidence of OA
alterations and standardize the size of histological sections
(Table I).
Table I
Location of the macroscopically observed osteoarthritic (OA)
changes in all groups
Site Articular surface area Predominant OA lesions
I Femoral trochlea Osteophytes
II Middle of the medial
femoral condyle
Severe ulceration
and loss of luster
III Middle of the lateral
femoral condyle
Modest ulceration
and loss of luster
IV Anterior part of the
medial and lateral
tibial plateau
Mild ulceration
and loss of luster
V Posterior part of the
medial and lateral
tibial plateau
Mild ulceration
and loss of luster
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mentioned sites and were stained with Haematoxyline/
Eosin (H/E), Periodic Acid Schiff’s (PAS), and Alcian
blue. For the microscopic evaluation, ﬁve histological pa-
rameters were taken into consideration: (1) morphology
of the articular cartilage, (2) morphology of the subchon-
dral bone, (3) thickness of the cartilage (comparison
between normal and affected sites), (4) arrangement of
chondrocytes into the hyaline cartilage, and (5) metabolic
activity of the chondrocytes. The ﬁrst two microscopic pa-
rameters (1, 2) were indicative of degeneration while the
last three (3e5) were evidence of a repairing and regener-
ation process.
In order to establish a more objective demonstration of
the histological parameters, a scoring system was used
(Table II). This scoring system was based on a modiﬁed
Mankin’s grading system18. Every histological parameter
was classiﬁed according to the severity of the osteoarthri-
tis on a scale from 0 to 5. Cartilage normal in appearance
was graded as 0 while the scale went up proportionally to
the severity of the OA lesion. The quantiﬁed classiﬁcation
of the histological ﬁndings was entered into a database
and statistical analysis was performed. The microscopicTable II
The evaluation of the natural history of the induced osteoarthritis
was based on five histological parameters scored according to
a modified Mankin’s grading system18
Articular cartilage morphology
Normal 0
Hypertrophy 1
Ulceration 2
Subchondral bone morphology
Normal 0
Cyst development 1
Cartilage thickness
Normal 0
Increase 1
Decrease 2
Arrangement of chondrocytes
Normal 0
Hypercellularity 1
Aggregation 2
Hypocellularity 3
Metabolic activity and chondrocytes
(PAS and Alcian blue staining)
Positive staining (anabolic stage) 0
Negative staining (catabolic phase) 1Fig. 1. Macroscopical appearance of a calcitonin prophylactic-stage group: femoral condyle (A), femoral trochlea (B), tibial plateau (C), and
a placebo prophylactic-stage group: femoral condyle (D), femoral trochlea (E), tibial plateau (F).
389Osteoarthritis and Cartilage Vol. 15, No. 4Fig. 2. Microscopical sections of the medial femoral condyle showing histological changes of the articular cartilage in a prophylactic-stage
group: calcitonin prophylactic-stage 4 (A), calcitonin prophylactic-stage 10 (B), placebo prophylactic-stage 4 (C), placebo prophylactic-
stage 10 (D). Notice articular thickness, chondrocyte distribution and subchondral cysts (hematoxylin/eosin staining, 4 and 10
magniﬁcations).measurement of the cartilage thickness was performed un-
der a magniﬁcation of 10 in increments of 0.01 mm real
thickness (1 cm of the microscopic scale corresponds to
0.39 mm of real thickness). The total score of all ﬁve
parameters characterized the severity of the OA changes
in every histological section. Adding the score from all his-
tological sections of each animal summed the total score
for that animal. The sum of the total scores of all the ani-
mals of each group produced the median and the mean
values that were used for the statistical analysis of the
results.
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS statistical
software (SPSS Inc, Chicago, IL, USA). Comparisons
between groups were performed using the Student’s t test
for the macroscopic parameters (quantitative data) and
non-parametric Wilcoxon test was used to analyze the his-
tological parameters (ordinal data). A value of P< 0.05 was
selected to indicate statistical signiﬁcance.Results
OA changes developed in all animals. The predominant
macroscopically observed OA changes in all groups were:
osteophytes in site I (trochlea), severe ulceration in site II
(medial femoral condyle), medium ulceration in site III
(lateral femoral condyle), and mild ulceration as well as
marginal osteophytes in sites IV and V (tibial plateaus)
(Table I).
Macroscopically, both calcitonin groups showed
smoother articular surfaces resembling the healthy carti-
lage, smaller osteophytes and no obvious ulcerations
when compared to the placebo groups (Figs. 1 and 2)
(Table III). The placebo groups showed ﬁbrillation of the
cartilage, larger osteophytes and ulceration of the articular
cartilage in the weight bearing areas of both femour and
tibia (Figs. 1 and 2) (Table III).
Microscopically, the morphology of articular cartilage in
the calcitonin prophylactic-stage group showed a more
normal appearance in comparison to the placebo prophy-
lactic-stage group (P¼ 0.002) (Fig. 3) (Table III). Although
those differences were also evident between theTable III
Macroscopical and microscopical findings showing the differences between the four treatment groups. Percentages express the number of
specimens that demonstrated these findings in each group (NS¼ not significant)
Prophylactic-stage groups Therapeutic-stage groups
Calcitonin (%) Placebo (%) P value Calcitonin (%) Placebo (%) P value
Osteophytes 37.5 40 NS 46.7 43.3 NS
Ulcerations 12.5 46.7 0.001 13.3 43.3 0.02
Normal cartilage appearance 37.5 8.9 0.002 30 13.3 NS
390 N. A. Papaioannou et al.: Role of calcitonin in osteoarthritisFig. 3. Macroscopical appearance of a calcitonin therapeutic-stage group: femoral condyle (A), femoral trochlea (B), tibial plateau (C) and a
placebo therapeutic-stage group: femoral condyle (D), femoral trochlea (E), tibial plateau (F).therapeutic-stage groups, they did not reach statistical sig-
niﬁcance (Fig. 4) (Table III). In the calcitonin groups, rare
ulceration and slight increasing of chondrocyte layers
were noticed. Furthermore, in the calcitonin groups, the os-
teophytes were smaller in size than the osteophytes in the
placebo groups. Additionally, the osteophytes in the calci-
tonin groups had a tendency of central reossiﬁcation (with-
out any evidence of endochondral bone formation) while
the osteophytes in the placebo groups had a necrotic
(non-cellular) central area (Table III). There were statisti-
cally signiﬁcant differences when the size of the articular
cartilage and the subchondral cystic formation were com-
pared between groups. Cartilage ulceration and subchon-
dral cysts were more evident in the placebo groups
(Table IV). Comparison of the articular cartilage thickness
in healthy and affected areas did not reveal statistical sig-
niﬁcance (Table V). However, cartilage was thicker in the
calcitonin groups than in the placebo groups. The distribu-
tion of chondrocytes (Table VI) in areas with mild OA
lesions was normal in calcitonin groups or slightly hyper-
cellular indicating regenerative activity (median value
0 for prophylactic stage and 2 for therapeutic stage)
whereas in the placebo groups, hypocellularity or aggrega-
tion of the chondrocytes was found (median value 2). PAS
and Alcian blue staining (Table VII), indicating themetabolic activity of the cartilage, was positive in the ma-
jority of the calcitonin group specimens and in the minority
of the placebo group specimens. Additionally, in the calci-
tonin groups increased absorption of PAS stain from the
nuclei and Alcian blue stain from the cytoplasm indicated
the high anabolic phase of the chondrocytes including res-
toration of mucopolysacharides and acidic-mucopolysa-
charides in sites of mild OA defects.
Generally, the above described changes were noticed
with statistical signiﬁcance mainly at the lateral femoral
condyle (site III) and posterior tibial plateau (site IV) in pro-
phylactic stages (Fig. 5) whereas trochlea (site I) was more
affected in therapeutic stages (Fig. 6).
Discussion
It is recently recognized that different joint compo-
nents contribute to progression of the osteoarthritis19,20.
Therefore, an ideal medication for its therapy should
have a favorable impact on the different aspects of the
disease process, including structural and metabolic
changes of the joint components. Seeking the ideal
drug, calcitonin seems to fulﬁll many requested criteria
such as safety at therapeutic doses11, analgesia on
391Osteoarthritis and Cartilage Vol. 15, No. 4Fig. 4. Microscopical sections of the medial femoral condyle showing histological changes of the articular cartilage in a therapeutic-stage
group: calcitonin therapeutic-stage 4 (A), calcitonin therapeutic-stage 10 (B), placebo therapeutic-stage 4 (C), placebo therapeutic-stage
10 (D). Notice articular thickness, chondrocyte distribution and hypochondral cysts (hematoxylin/eosin staining, 4 and 10 magniﬁcations).the clinical management of the disease12,13,21, anti-
inﬂammatory properties22e27 and positive effect on the
morphology and metabolism of both subchondral bone
and articular cartilage28e30.
The positive effect of calcitonin on bone metabolism is
based on histological studies showing that the hormone im-
proves the rate of bone turnover, the organization of trabec-
ulae and the quality of bone matrix deposition in patients
with Paget disease29 and in patients with osteoarthritis28,30.
This positive effect on bone mineralization and its structural
organization improves signiﬁcantly the biomechanical prop-
erties of the subchondral bone tissue31,32. Additionally,
in vitro studies exhibited a stimulatory effect of calcitonin
on the cartilage chondrocytes production of proteoglycans
and collagen-II33e35. Furthermore, calcitonin reduces the
collagenase activity present in OA cartilage explants27,34.The strongest evidence for calcitonin as a potential agent
for the treatment of human osteoarthritis arises from the re-
sults of pre-clinical animal studies. In a rabbit model, the
hormone hampers the loss of cartilage glycosaminogly-
cans35 and in canine models of experimental osteoarthritis,
calcitonin prevented periarticular osteopenia, reduced joint
inﬂammation, turnover markers, synovial proliferation
markers, aggrecan metabolism markers, and bone resorp-
tion markers14,15. In another canine experimental osteoar-
thritis study, calcitonin reduced the hyaluronan and
collagen loss associated with the development of OA
changes20 .
The macroscopical and histological ﬁndings of this study
supported the results of the above experimental studies in-
dicating the chondro-protective and chondro-regenerative
roles of salmon calcitonin in experimentally inducedTable IV
There were statistically significant differences when the size of the articular cartilage (with interval 0.01 mm of real thickness) and the subchon-
dral cystic formation were compared between groups. Minimum and maximum values in the parentheses were according to the modified
Mankin’s grading system18 and represent the summary from all the sites
Groups Minimum and maximum values
Chondral morphology
(hypertrophy, ulceration)
Subchondral morphology
(cysts)
Calcitonin prophylactic-stage (3e7) P¼ 0.05 (3e9) P¼ 0.012
Placebo prophylactic-stage (3e12) (9e15)
Calcitonin therapeutic-stage (2e7) P¼ 0.005 (6e15) P¼ 0.002
Placebo therapeutic-stage (5e12) (12e15)
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Comparison of the articular cartilage thickness in healthy and affected areas (areas of normal vs osteoarthretic from the same anatomic site
which was the medial femoral condyle) (measurements are in mm)
Prophylactic-stage calcitonin vs placebo Therapeutic-stage calcitonin vs placebo
Areas of normal appearance 3.9* 0.8 vs 3.4* 0.6, P¼ 0.01 4.1a 1.3 vs 4.4a 0.9, P¼NS
Areas of mild OA changes 8.7a 3.4 vs 7.7a 2.5, P¼NS 9.5a 1.9 vs 9.3a 1.2, P¼NS
Areas of severe OA changes 1.1a 0.6 vs 0.6a 0.4, P¼NS 1.2a 0.9 vs 0.8a 0.5, P¼NS
*Statistically signiﬁcant when P< 0.05.
aWith interval 0.01 mm of real thickness.arthritis. The placebo prophylactic-stage group conﬁrmed
the development of osteoarthritis 8 weeks after the transec-
tion of the CCL and the experimentally induced knee insta-
bility. A recent study by the same authors showed that
a period of 8 weeks after CCL transection was sufﬁcient
for the development of OA lesions in rabbit knees36.
Macroscopically, in the placebo prophylactic-stage
group, osteophyte formation was predominantly noted at
the proximal part of the femoral trochlea (site I) and severe
ulceration and loss of luster were prominently noted at me-
dial femoral condyle (site II). The combination of two bio-
mechanical factors may explain the predominant and
signiﬁcant macroscopic OA ﬁndings at the trochlea. Firstly,
the patello-femoral articulation is the most mobile site of
the knee and the friction of the articular cartilage at this
area is greater than that in other sites of the joint. Sec-
ondly, the ﬂexion of the rabbit’s knee at the standing
position contributes to the greater loading of the patello-
femoral articulation37. Calcitonin prophylactic-stage group
showed a more normal appearance than the placebo pro-
phylactic-stage group indicating the chondro-protective
role of the hormone. Calcitonin therapeutic-stage group
showed evidences of cartilage healing with smaller osteo-
phytes than the placebo therapeutic-stage group, support-
ing the repairing (chondro-therapeutic) role of the
hormone.
Microscopically, both calcitonin groups showed rare
cartilage ulceration and increasing layers of chondrocytes.
That ﬁnding was in accordance with previous in vitro
studies showing that the hormone, in a dose-dependent
manner, had a stimulatory effect on the cell production
of proteoglycans and type II collagen33,34,38. Further, cal-
citonin signiﬁcantly reduced the collagenase activity in OA
articular cartilage explants27,34. Regarding the subchon-
dral bone morphology, smaller osteophytes, with a ten-
dency of reossiﬁcation, and cystic formations were
observed in both calcitonin groups than in the placebo
groups. Those ﬁndings supported previous knowledge
that salmon calcitonin improved bone turnover, the
Table VI
Comparison of the distribution of chondrocytes between groups.
Median, minimum and maximum values are according to modified
Mankin grading system.18
Median value [minimum and maximum values]
Prophylactic-stage
calcitonin vs placebo
Therapeutic-stage
calcitonin vs placebo
Sites with mild
OA changes
0/2 [0e3/0e3],
P¼ 0.000
2/2 [0e3/2e3],
P¼NS
OA: osteoarthritic.structure of trabeculae and the quality of bone matrix
deposition28e30. The number of chondrocytes in areas
with mild OA lesions was normal in both calcitonin groups
or a hypercellularity was noticed indicating regenerative
activity. Additionally, nuclei and matrix staining in both
calcitonin groups revealed signiﬁcantly higher metabolic
activity when compared with the placebo group. That ﬁnd-
ing supports the above-mentioned role of calcitonin that
stimulates the production of proteoglycans and type II
collagen33,34,38.
The above reported in vitro and in vivo observations
and many recent pre-clinical studies conducted mostly
in animal OA models offer the strongest arguments for
calcitonin as a potential agent for the treatment of human
osteoarthritis. The macroscopic and microscopic ﬁndings
of this study support the biochemical results of previous
studies and indicate that the administration of salmon cal-
citonin in rabbits inhibits the progress of experimentally
induced osteoarthritis (chondro-protective role of calcito-
nin). Furthermore, thickening of hyaline cartilage layers,
healing of ulcerations, smaller size of osteophytes than
in placebo group, and restoration of chondrocytes’ meta-
bolic activity demonstrate the regenerative effect of
calcitonin on the cartilage and subchondral bone (chon-
dro-therapeutic role). Conclusively, calcitonin treatment
contributed to the observed reduction in the score of
the OA microscopic lesions indicating a clear chondro-
protective and chondro-regenerative roles against post-
traumatic arthritis.
There are some limitations to this study. Firstly, our ex-
perimental model produced chondral changes induced af-
ter an acute traumatic event such as CCL transection.
Therefore, we should not compare these changes with
the slowly progressive ones in degenerative arthritis.
CCL transection results in a true instability-induced OA le-
sion that mimics osteoarthritis occurring naturally in hu-
mans following traumatic injury39e41. Secondly, given the
Table VII
Comparison of the metabolic activity of the chondrocytes between
groups. Increased metabolic activity was noticed in the calcitonin
groups. Percentages express the number of specimens showed
positive staining in each group
Prophylactic-stage group Therapeutic-stage group
Calcitonin
(%)
Placebo
(%)
P
value
Calcitonin
(%)
Placebo
(%)
P
value
PAS
(positive)
56.4 26.7 0.008 73.3 43.3 0.03
Alcian
blue
(positive)
61.5 28.9 0.004 76.7 50 0.06
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* MFC = medial femoral condyles, LFC = lateral femoral condyles, TP = tibial plateau 
Site
Fig. 5. In the prophylactic-stage groups, the calcitonin effect was signiﬁcantly greater on the lateral femoral condyles (site III) and the posterior
half of tibial plateau (site V).marked differences in anatomy, biomechanics and kinetics
of the rabbit and human knee37,42,43, we should comment
on the applicability of this model, in which the most strik-
ing macroscopic changes occurred on the trochlea, rather
than in the tibiofemoral compartment, as is usual in hu-
man osteoarthritis. Another consideration is that it might
be improper to draw conclusions on the metabolic activity
of the chondrocytes based only on histochemical data.
Isotopic studies or studies of synthesis or degradation of
cartilage matrix macromolecules would also be appropri-
ate for such interpretations. The last would clarify if the
observed cartilage thickening is a part of a regenerative
process or the ﬁrst phase of a progressive arthritis.However, we correlated our macroscopic and microscopic
results with the biochemical ﬁndings of other experimental
studies. Finally, a reader of this study could say that we
lump together changes of degeneration and regeneration
by providing a total score as an index of histological se-
verity of osteoarthritis and that it would be better to exam-
ine these microscopic parameters separately. Since the
natural history of induced osteoarthritis includes both de-
generative and regenerative processes36, we thought
that the total score of all the above-mentioned microscopic
parameters would be more representative of the ﬁnal ef-
fect of salmon calcitonin on the OA cartilage and sub-
chondral bone.Comparison of total score between the therapeutic stage groups
0
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10
12
M
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p=0,023
* MFC = medial femoral condyles, LFC = therapeuticral femoral condyles, TP = tibial plateaux 
Trochlea MFC LFC
Site
Anterior TP Posterior TP
Calcitonin therapeutic group
Placebo therapeutic group
Fig. 6. In the therapeutic-stage groups, the calcitonin effect was signiﬁcantly greater on the femoral trochlea (site I).
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